GNTA logo

Genenta Science SpA (GNTA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Italy

IPO:

15 December 2021

Indexes:

Not included

Description:

Genenta Science SpA is a biotechnology company focused on developing innovative gene therapies for cancer treatment. They use a unique approach to deliver therapeutic genes directly to patients' immune cells, aiming to enhance the body's ability to fight tumors and improve patient outcomes.

Events Calendar

Earnings

Next earnings date:

Jan 07, 2025

Recent quarterly earnings:

Apr 26, 2023

Recent annual earnings:

Apr 26, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

02 Oct '24 HC Wainwright & Co.
Buy
13 May '24 HC Wainwright & Co.
Buy
08 Feb '23 HC Wainwright & Co.
Buy
05 Jan '23 EF Hutton
Buy
25 July '22 HC Wainwright & Co.
Buy
13 Jan '22 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
GNTA
globenewswire.com23 October 2024

Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
GNTA
globenewswire.com02 October 2024

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA).

Genenta to Present at Upcoming Scientific and Investor Conferences
Genenta to Present at Upcoming Scientific and Investor Conferences
Genenta to Present at Upcoming Scientific and Investor Conferences
GNTA
GlobeNewsWire06 September 2023

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.

FAQ

  • What is the primary business of Genenta Science SpA?
  • What is the ticker symbol for Genenta Science SpA?
  • Does Genenta Science SpA pay dividends?
  • What sector is Genenta Science SpA in?
  • What industry is Genenta Science SpA in?
  • What country is Genenta Science SpA based in?
  • When did Genenta Science SpA go public?
  • Is Genenta Science SpA in the S&P 500?
  • Is Genenta Science SpA in the NASDAQ 100?
  • Is Genenta Science SpA in the Dow Jones?
  • When was Genenta Science SpA's last earnings report?
  • When does Genenta Science SpA report earnings?

What is the primary business of Genenta Science SpA?

Genenta Science SpA is a biotechnology company focused on developing innovative gene therapies for cancer treatment. They use a unique approach to deliver therapeutic genes directly to patients' immune cells, aiming to enhance the body's ability to fight tumors and improve patient outcomes.

What is the ticker symbol for Genenta Science SpA?

The ticker symbol for Genenta Science SpA is NASDAQ:GNTA

Does Genenta Science SpA pay dividends?

No, Genenta Science SpA does not pay dividends

What sector is Genenta Science SpA in?

Genenta Science SpA is in the Healthcare sector

What industry is Genenta Science SpA in?

Genenta Science SpA is in the Biotechnology industry

What country is Genenta Science SpA based in?

Genenta Science SpA is headquartered in Italy

When did Genenta Science SpA go public?

Genenta Science SpA's initial public offering (IPO) was on 15 December 2021

Is Genenta Science SpA in the S&P 500?

No, Genenta Science SpA is not included in the S&P 500 index

Is Genenta Science SpA in the NASDAQ 100?

No, Genenta Science SpA is not included in the NASDAQ 100 index

Is Genenta Science SpA in the Dow Jones?

No, Genenta Science SpA is not included in the Dow Jones index

When was Genenta Science SpA's last earnings report?

Genenta Science SpA's most recent earnings report was on 26 April 2023

When does Genenta Science SpA report earnings?

The next expected earnings date for Genenta Science SpA is 7 January 2025